Holen Sie sich die Stockscreener-App
3.45
1.47%
0.05
Handel nachbörslich:
3.45
Schlusskurs vom Vortag:
$3.40
Offen:
$3.43
24-Stunden-Volumen:
89,406
Relative Volume:
1.49
Marktkapitalisierung:
$176.19M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-103.21M
KGV:
-0.75
EPS:
-4.6001
Netto-Cashflow:
$-26.70M
1W Leistung:
+16.55%
1M Leistung:
-12.88%
6M Leistung:
-54.78%
1J Leistung:
-75.69%
1-Tages-Spanne:
$3.29
$3.69
1-Wochen-Bereich:
$2.65
$3.69
52-Wochen-Spanne:
$2.65
$13.84
Engene Holdings Inc Stock (ENGN) Company Profile
Firmenname
Engene Holdings Inc
Sektor
Branche
Telefon
(514) 332-4888
Adresse
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
Vergleichen Sie ENGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENGN
Engene Holdings Inc
|
3.45 | 150.89M | 0 | -103.21M | -26.70M | -4.6001 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Engene Holdings Inc Stock (ENGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-18 | Eingeleitet | Piper Sandler | Overweight |
| 2025-02-14 | Herabstufung | UBS | Buy → Neutral |
| 2024-12-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-27 | Eingeleitet | Raymond James | Outperform |
| 2024-11-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-08-28 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-22 | Eingeleitet | Wells Fargo | Overweight |
| 2024-04-15 | Eingeleitet | Guggenheim | Buy |
| 2024-03-28 | Eingeleitet | UBS | Buy |
| 2024-03-08 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-20 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Engene Holdings Inc Aktie (ENGN) Neueste Nachrichten
Is enGene Holdings (NASDAQ:ENGN) Using Too Much Debt? - simplywall.st
(ENGN) Trading Signals - news.stocktradersdaily.com
Citizens JMP reiterates Engene stock with $18 target By Investing.com - Investing.com Nigeria
Citizens JMP reiterates Engene stock with $18 target - Investing.com
enGene to Participate in Upcoming Investor Conferences - Yahoo Finance
enGene to Participate in Upcoming May 2025 Investor Conferences - BioSpace
enGene Holdings Inc.'s (NASDAQ:ENGN) largest shareholders are private equity firms with 38% ownership, institutions own 35% - Yahoo Finance
Is enGene Holdings Inc. (ENGN) the Best Canadian Penny Stock to Invest in Now? - Insider Monkey
(ENGN) Technical Data - news.stocktradersdaily.com
enGene (NASDAQ:ENGN) & Innate Pharma (OTCMKTS:IPHYF) Head-To-Head Survey - Defense World
enGene Holdings Inc. (NASDAQ:ENGN) Receives Average Rating of “Buy” from Analysts - Defense World
Trend Tracker for (ENGN) - news.stocktradersdaily.com
Engene Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
enGene Expands Team with New Hires, Grants 144,650 Shares in Stock Options - Stock Titan
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
Strategic Oncology Updates Coming: enGene CEO Headlines Stifel Healthcare Forum - Stock Titan
How the (ENGN) price action is used to our Advantage - news.stocktradersdaily.com
Promising Trajectory and Strong Financial Position Justify Buy Rating for enGene Holdings - TipRanks
enGene Holdings Insider Ups Holding During Year - Yahoo Finance
enGene Holdings Inc.'s (NASDAQ:ENGN) market cap dropped US$33m last week; individual investors who hold 38% were hit as were institutions - Simply Wall St
enGene’s (ENGN) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
enGene (NASDAQ:ENGN) Price Target Lowered to $34.00 at Morgan Stanley - Defense World
Engene stock holds Buy rating, $25 target from H.C. Wainwright - Investing.com
Engene stock holds Buy rating, $25 target from H.C. Wainwright By Investing.com - Investing.com South Africa
enGene Reports First Quarter 2025 Financial Results and Provides Business Update - BioSpace
enGene Holdings Inc. SEC 10-Q Report - TradingView
enGene Reports Q1 Results: Strong Cash Position Funds Global Trial Expansion - StockTitan
Trading (ENGN) With Integrated Risk Controls - Stock Traders Daily
enGene to Participate in the Leerink Partners Global Healthcare Conference - Business Wire
What Will enGene Reveal? CEO's Upcoming Fireside Chat at Major Healthcare Conference - Stock Titan
Lumira Ventures Portfolio Company enGene (Nasdaq:ENGN) Debuts as Publicly Traded Genetic Medicines Company - ACCESS Newswire
enGene Holdings Inc.: Unknown Company Which Looks Like A Catch (NASDAQ:ENGN) - Seeking Alpha
Financial Contrast: enGene (NASDAQ:ENGN) versus iTeos Therapeutics (NASDAQ:ITOS) - Defense World
(ENGN) On The My Stocks Page - Stock Traders Daily
Vontobel Holding Ltd. Makes New $69,000 Investment in enGene Holdings Inc. (NASDAQ:ENGN) - Defense World
enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
enGene (NASDAQ:ENGN) Coverage Initiated at Piper Sandler - Armenian Reporter
enGene Holdings GAAP EPS of -$0.38 - MSN
New Strong Buy Stocks for February 19th - Zacks Investment Research
enGene (NASDAQ:ENGN) Now Covered by Piper Sandler - Defense World
Best Momentum Stocks to Buy for February 19th - Yahoo Finance
enGene Holdings Inc. (NASDAQ:ENGN) Given Average Rating of “Buy” by Brokerages - Defense World
Piper Sandler sets $26 target on Engene shares with Overweight rating - Investing.com Australia
This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Buy Rating for enGene Holdings: Strategic Positioning and Growth Potential in NMIBC Market - TipRanks
Piper Sandler Initiates Coverage on enGene Holdings With Overweight Rating, $26 Price Target - Marketscreener.com
Piper Sandler sets $26 target on Engene shares with Overweight rating By Investing.com - Investing.com South Africa
Analyzing Ratios: enGene Holdings Inc (ENGN)’s Financial Story Unveiled - The Dwinnex
enGene (NASDAQ:ENGN) Stock Rating Lowered by UBS Group - Defense World
enGene (NASDAQ:ENGN) Downgraded to Neutral Rating by UBS Group - MarketBeat
Sector Update: Health Care -February 14, 2025 at 03:41 pm EST - Marketscreener.com
Finanzdaten der Engene Holdings Inc-Aktie (ENGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Engene Holdings Inc-Aktie (ENGN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Forbion Growth Opportunities F | 10% Owner |
Sep 30 '24 |
Buy |
6.34 |
341,332 |
2,163,362 |
2,400,791 |
| Forbion Growth Opportunities F | 10% Owner |
Sep 27 '24 |
Buy |
5.97 |
41,639 |
248,699 |
2,059,459 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 01 '24 |
Buy |
6.44 |
35,279 |
227,158 |
2,436,070 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 07 '24 |
Buy |
6.55 |
11,844 |
77,531 |
2,469,833 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 02 '24 |
Buy |
6.37 |
10,153 |
64,697 |
2,446,223 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 04 '24 |
Buy |
6.54 |
5,997 |
39,242 |
2,457,989 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 03 '24 |
Buy |
6.48 |
5,769 |
37,397 |
2,451,992 |
| Forbion Growth Opportunities F | 10% Owner |
Oct 08 '24 |
Buy |
6.60 |
800 |
5,278 |
2,470,633 |
| Cooper Ronald Harold Wilfred | Chief Executive Officer |
Sep 27 '24 |
Buy |
5.70 |
10,000 |
57,000 |
10,000 |
| Glickman Richard M | Director |
May 28 '24 |
Option Exercise |
0.89 |
120 |
107 |
24,675 |
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):